Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2019 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: BulbaMan who wrote (115)	2/16/2019 1:48:53 PM
From: ghmm	Read Replies (2) \| Respond to of 280

Axovant did change the symbol to AXGT but Arvelle is actually a new company that will be getting their small molecule programs. They'll own 5% preferred shares. They have investors commiting up to 100M. Not sure if it will be public. From the contest, perspective don't know if anyone aside from me has it but I would be OK with you completely ignoring that element to keep things easy.

To: BulbaMan who wrote (115)	2/23/2019 12:37:35 AM
From: BulbaMan	Read Replies (3) \| Respond to of 280

2/22/2019 Contest update This week’s Trillium tsuris did further damage to the ten portfolios holding the stock, with the Contest median negatively impacted as well. At Friday’s close, the Contest median was up 14.57% YTD (vs. 16.30% YTD a week ago), the Nasdaq Biotech Index (NBI) was up 14.42% YTD (vs. 15.67% YTD a week ago), the smaller-cap S&P Biotechnology Select Industry Index (SPSIBI) was up 19.08% YTD (vs. 20.26% YTD a week ago) and the Nasdaq Composite Index (NCI) was up 13.45% YTD (vs. up 12.62% YTD a week ago). There was no collusion, yet for this Presidents’ Day week three of my Contest portfolio stocks, IMDZ, ZIOP, MGTA, were elected for “Top 5 Gainers of the Week” honors. The Number One kahuna, of course, was IMDZ. It surged 299% following a Merck buyout at a jumbo premium and was the main force propelling my portfolio to first place with a 48.37% YTD gain. HOOD’s portfolio, up 41.60% YTD, had to be content with second place and the only other IMDZ holder, OHMS portfolio, took over third place with a 39.92% YTD gain. At Friday's close, 36 of the 39 Contest portfolios were in the green, with 20 beating the NBI and 13 still beating the SPSIBI. All three portfolios in the red were TRIL holders. The 167 Contest stock picks have an average YTD gain of 21.21% and a median YTD gain of 18.49%. Below is the Top Ten list. Also below are the Top 5 & Bottom 5 Stocks for the week ranked by % Gained and % Lost YTD. (Prices not converted to US$ in these Tables.) Portfolio adjustments: Axovant (AXON) changed its name and symbol to Arvelle Therapeutics (AXGT). After Yahoo Quotes made the change I switched the symbols. Only GHMM’s portfolio had AXON, now AXGT. (All corrections, especially adjustments for splits & mergers, greatly appreciated.) Enjoy a safe & fun weekend biotechies! Peace & good health, Bulba 2/22/19 Rank Name Profit/Loss 1 BULBA 48,366 2 HOOD 41,598 3 OHMS 39,919 4 SANCTU 36,151 5 RKRW 30,872 6 JACKH 29,609 7 BIOADD 26,078 8 DEWDIL 26,006 9 BIOPLAY 20,857 10 GENE 20,453 Week's Top 5 Gainers Symbol 2/8/19 2/22/19 Wk.%chg. IMDZ 1.460 5.830 299.32% NVTA 13.890 19.220 38.37% ZIOP 2.380 3.030 27.31% MGTA 7.490 9.390 25.37% MNTA 12.200 15.100 23.77% Week's Worst 5 Losers Symbol 2/8/19 2/22/19 Wk.%chg. KPTI 8.800 5.070 -42.39% TRIL 1.220 0.730 -40.19% XERS 14.900 9.850 -33.89% PTE 16.830 12.430 -26.14% ASLN 3.650 3.120 -14.52%